Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지

Clinical Efficacy of Pimobendan on Dogs with Chronic Mitral Valvular Diseases

만성 이첨판 폐쇄부전증 이환된 견에서 피모벤단의 임상적 효과

  • Nam, So-Jeong (Section of Small Animal Internal Medicine, School of Veterinary Medicine, Kangwon National University) ;
  • Park, In-Chul (Section of Diagnostic Imaging, School of Veterinary Medicine, Kangwon National University) ;
  • Hyun, Chang-Baig (Section of Small Animal Internal Medicine, School of Veterinary Medicine, Kangwon National University)
  • 남소정 (강원대학교 수의(학부)대학 소동물 내과교실) ;
  • 박인철 (강원대학교 수의(학부)대학 방사선학 교실) ;
  • 현창백 (강원대학교 수의(학부)대학 소동물 내과교실)
  • Published : 2009.02.27
Download PDF
⟨ Previous Next ⟩

Abstract

Pimobendan is a recently developed cardiac drug which is useful to control moderate to severe congestive heart failure (CHF) from chronic mitral valvular diseases (CMVI). Because of controversy related to the efficacy and safety of pimobendan in dogs, the optimal efficacy and safety of pimobendan was assessed in 20 dogs with CMVI in this study. Scores for quality of life, respiratory failure, circulatory failure and heart failure were evaluated along with radiographical and echocardiographical assessments for about 2 months period after the addition of pimobendan into the regular cardiac medications. This study proved clear evidence that pimobendan had beneficial therapeutic effects in dogs with advanced CMVI, without particular adverse effects. However, further studies are warranted to address the drug interaction with other cardiac therapeutics and to assess therapeutic effects in CHF from other type of heart diseases in dogs and other animals.

피모벤단은 최근에 발견되어, 만성 이첨판 폐쇄부전증에 의한 중등도에서 심한 울혈성 심부전을 관리하는데 유용하게 사용되는 심장성 약물이다. 아직까지 개에서 피모벤단의 효능과 안전성에 대한 의견이 분분하다. 따라서 본 연구는 최적의 효능과 안전성을 알아보기 위하여 만성 이첨판 폐쇄부전증에 이환된 20마리의 개를 평가하였다. 일반적인 심장 약물 처방에 피모벤단을 추가한 뒤 삶의 질, 호흡부전, 순환부전과 심부전의 상태를 방사선과 심초음파 검사와 함께 두 달간 평가하였다. 본 연구에서는 진행된 만성 이첨판 폐쇄부전증에 이환된 개에서 피모벤단이 특별한 부작용 없이 긍정적인 치료 효과를 보이는 것으로 나타났다. 그러나 다른 심장 처방약과 피모벤단의 상호 작용 효과에 중점을 둔 연구와 이첨판 폐쇄부전증이 아닌 다른 심장질병에 의한 개와 다른 동물의 심부전에 어떠한 치료효과를 보이는지 평가하는 추가적인 연구가 필요할 것이다.

Keywords

References

  1. Beardow AW, Buchanan JW. Chronic mitral valve disease in cavalier King Charles spaniels: 95 cases (1987–1991). J Am Vet Med Assoc 1993; 203: 1023–1029
  2. Bonagura JD, Herring DS. Echocardiography; Acquired heart disease. Vet Clin North Am Small Anim Pract. 1985; 15: 1209-1224
  3. Chu KM, Shieh SM, Hu OY. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. Clin Pharmacol Ther 1995; 57: 610-621 https://doi.org/10.1016/0009-9236(95)90223-6
  4. Fuentes VL, Corcoran B, French A, et al. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med 2002; 16: 255-261 https://doi.org/10.1111/j.1939-1676.2002.tb02366.x
  5. Fuentes VL. Use of pimobendan in the management of heart failure. Vet Clin North Am Small Anim Pract 2004; 34: 1145-1155 https://doi.org/10.1016/j.cvsm.2004.05.018
  6. Hagemeijer F. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Eur Heart J 1993; 14: 551-566. https://doi.org/10.1093/eurheartj/14.4.551
  7. H$\ddot{a}$ggstr$\ddot{o}$m J, Boswood A, O'Grady M, J$\ddot{o}$ns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kova evi A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, 'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, Difruscia R. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring oyxomatous mitral valve disease: The QUEST study. J Vet Intern Med 2008; 22: 1124-1135 https://doi.org/10.1111/j.1939-1676.2008.0150.x
  8. Haggstrom J, Hamlin RL, Hansson K. Heart rate variability in relation to severity of mitral regurgitation in Cavalier King Charles spaniels. J Small Anim Pract 1996; 37: 69–75 https://doi.org/10.1111/j.1748-5827.1996.tb01941.x
  9. Haggstrom J, Kvart C, Pedersen HD. Aquired valvular heart disease. In: Textbook of Veterinary Internal Medicine, 6 th ed. St Louis: Elsevier. 2005: 1022–1039
  10. Hyun C. Mitral valve prolapse in Cavalier King Charles spaniel: a review and case study. Vet Sci 2005; 6: 67-73
  11. Hyun C. Valvular disease. In: Textbook of Small Animal Cardiology, Seoul: Panmoon Publishing. 2005: 185–206
  12. Justin D. Thomason, Tiffany K. Fallaw, Clay A. Calvert. Pimobendan: Understanding its cardiac effects in dogs with myocardial disease. Vet Med 2006: 660-667
  13. Kittleson MD, Kienle RD. Myxomatous atrioventricular valvular degeneration. In: Small Animal Cardiovascular Medicine. St Louis: Mosby. 1998: 297–318
  14. Kleeman R, Lebobinnee G, Bruyere D. Clinical efficacy of the novel inodilator pimobendan in dogs suffering from congestive heart failure, in Proceedings. Br Small Anim Vet Congress 1998
  15. Lefbon BK. Sildenafil and novel cardiovascular therapies, in Proceedings. Am Coll Vet Intern Med 2005; 75-80.
  16. Lombard CW, Jons O, Bussadoril CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006; 42: 249-261
  17. Moon HS, Choi E, Hyun C. The cardiac sodium-calcium exchanger gene (NCX-1) is a potential canine cardiac biomarker of chronic mitral valvular insufficiency. J Vet Intern Med 2008; 22: 1360-1365 https://doi.org/10.1111/j.1939-1676.2008.0209.x
  18. Pouchelon JL, Jamet N, Gouni V, Tissier R, Serres F, Carlos Sampedrano C, Castaignet M, Lefebvre HP, Chetboul V. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases. J Vet Intern Med. 2008; 22: 905-914 https://doi.org/10.1111/j.1939-1676.2008.0105.x
  19. Rosenthal SL, Ferguson MJ, Lefbom BK. Association of pimobendan with ventricular arrhythmias in dogs with congestive heart failure, in Proceedings. Am Coll Vet Intern Med 2006; 110-115
  20. Serres F, Chetboul V, Tissier R, Poujol L, Gouni V, Carlos Sampedrano C, Pouchelon JL, 'Comparison of 3 ultrasound methods for quantifying left ventricular systolic function: correlation with disease severity and prognostic value in dogs with mitral valve disease', J Vet Intern Med. 2008; 22: 566-577 https://doi.org/10.1111/j.1939-1676.2008.0097.x
  21. Smith PJ, French AT, Van Israel N. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract 2005; 46: 121-130 https://doi.org/10.1111/j.1748-5827.2005.tb00302.x
  22. Wess G. Assessment of left ventricular systolic and diastolic function in canine myxomatous mitral valve disease using myocardial tissue Doppler imaging. In: International canine valvular disease symposium, Stockholm, Sweden. 2008: 44-45